• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

MEDROXYPROGESTERONE ACETATE Drug Record

  • Summary
  • Interactions
  • Claims
  • MEDROXYPROGESTERONE ACETATE chembl:CHEMBL717 Approved

    Alternate Names:

    FARLUTAL 250
    SAYANA PRESS
    DEPO-PROVERA
    DEPO-PROGEVERA
    FARLUTAL
    CLIMANOR
    CURRETAB
    FARLUTAL 200
    MEDROXYPROGESTERONE 17-ACETATE
    TV-46046
    ADGYN MEDRO
    AMEN
    MEDROXYPROGESTERONE ACETATE
    FARLUTAL 500
    MEDROXIPROGESTERONE ACETATE
    NSC-26386
    CYCRIN
    LUNELLE
    DEPO-SUBQ PROVERA 104
    MEDROXYPROGESTERONE
    DEPO-PROVERA ONCOLOGY
    PROVERA
    FARLUTAL 100
    PREMPRO
    NSC-21171
    6Α-METHYL-17Α-HYDROXYPROGESTERONE ACETATE
    6ALPHA-METHYL-4-PREGNENE-3,20-DION-17ALPHA-OL ACETATE
    MEDROXYACETATE PROGESTERONE
    MPA
    METIGESTRONA
    6ALPHA-METHYL-17ALPHA-HYDROXYPROGESTERONE ACETATE
    17ALPHA-HYDROXY-6ALPHA-METHYLPROGESTERONE ACETATE
    6-ALPHA-METHYL-17-ALPHA-HYDROXYPROGESTERONE ACETATE
    17-ACETOXY-6ALPHA-METHYLPROGESTERONE
    6-ALPHA-METHYL-17-ALPHA-ACETOXYPROGESTERONE
    6Α-METHYL-17-ACETOXY PROGESTERONE
    6ALPHA-METHYL-17-ACETOXY PROGESTERONE
    (6ALPHA)-17-(ACETYLOXY)-6-METHYLPREG-4-ENE-3,20-DIONE
    17-ACETOXY-6Α-METHYLPROGESTERONE
    17Α-HYDROXY-6Α-METHYLPROGESTERONE ACETATE
    METHYLACETOXYPROGESTERONE
    chemidplus:71-58-9
    chembl:CHEMBL717
    rxcui:1000112
    drugbank:00603
    pubchem.compound:6279

    Drug Info:

    (2 More Sources)

    Publications:

    Helguero et al., 2003, Progesterone receptor expression in medroxyprogesterone acetate-induced murine mammary carcinomas and response to endocrine treatment., Breast Cancer Res. Treat.
    Vereide et al., 2005, Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone., Gynecol. Oncol.
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Deng HW et al., 1998, Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes., Hum Genet
    Fitton et al., 1998, Assessment of anticollagenase treatments after insertion of a keratoprosthetic material in the rabbit cornea., Cornea
    Bulun et al., 2000, Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues., Am. J. Obstet. Gynecol.
  • MEDROXYPROGESTERONE ACETATE   MMP1

    Interaction Score: 0.52

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9436888


    Sources:
    NCI

  • MEDROXYPROGESTERONE ACETATE   PGR

    Interaction Score: 0.35

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Progesterone receptor agonist

    PMIDs:
    12846422


    Sources:
    ChemblInteractions NCI TTD

  • MEDROXYPROGESTERONE ACETATE   CYP1B1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10764452


    Sources:
    NCI

  • MEDROXYPROGESTERONE ACETATE   ERG

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   BAX

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15885761


    Sources:
    NCI

  • MEDROXYPROGESTERONE ACETATE   CYP3A5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • MEDROXYPROGESTERONE ACETATE   NPSR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   RORC

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   ESR1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9860300


    Sources:
    PharmGKB

  • MEDROXYPROGESTERONE ACETATE   VDR

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9860300


    Sources:
    PharmGKB

  • MEDROXYPROGESTERONE ACETATE   ALDH1A1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   NFE2L2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   AR

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • MEDROXYPROGESTERONE ACETATE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: MEDROXYPROGESTERONE

    • Version: 14-September-2017

    Alternate Names:
    C629 NCI drug code

    Drug Info:

    Publications:
    Vereide et al., 2005, Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone., Gynecol. Oncol.
    Bulun et al., 2000, Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues., Am. J. Obstet. Gynecol.
    Fitton et al., 1998, Assessment of anticollagenase treatments after insertion of a keratoprosthetic material in the rabbit cornea., Cornea

  • PharmGKB: medroxyprogesterone

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Deng HW et al., 1998, Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes., Hum Genet

  • DTC: MEDROXYPROGESTERONE ACETATE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL717 ChEMBL Drug ID

    Drug Info:

    Publications:

  • TTD: Medroxyprogesterone

    • Version: 2020.06.01

    Alternate Names:
    D0I2SD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL717

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL717

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21